Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. The company is headquartered in New York, New York.
| Revenue (TTM) | $1.34M |
| Gross Profit (TTM) | $1.34M |
| EBITDA | $-191.17M |
| Operating Margin | -10050.00% |
| Return on Equity | -22.70% |
| Return on Assets | -15.00% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $22.01 |
| Price-to-Book | 4.29 |
| Price-to-Sales (TTM) | 3918.29 |
| EV/Revenue | 3029.43 |
| EV/EBITDA | -7.35 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -60.20% |
| Shares Outstanding | $54.67M |
| Float | $54.60M |
| % Insiders | 0.13% |
| % Institutions | 120.67% |
Volatility is currently contracting
NEW YORK and WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on July 1, 2026, to five newly-hired, non-executive employees.
EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W vs. placebo, with top-line results anticipated in 2H'28
Dianthus Therapeutics stock climbs 89% in six months as claseprubart advances across key autoimmune studies. Strong cash position supports development into 2030.
Dianthus Therapeutics, Inc. (DNTH) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
NEW YORK and WALTHAM, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on June 1, 2026, to three newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).
NEW YORK and WALTHAM, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company's participation in two investor conferences in June 2026.
Company announces $30 million Series A financing and founding leadership team with expertise in pulmonary drug innovation and track record advancing novel therapies to patients
NANJING, China, May 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs"; Stock Code: 9887.HK) today announced that its partner, Dianthus Therapeutics, Inc. (“Dianthus”; NASDAQ: DNTH), has selected Sjögren's disease (SjD), systemic lupus erythematosus (SLE), and dermatomyositis (DM) as the first three priority indications for clinical development of LBL-047 (known as DNTH212 outside Greater China).
Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A
